EUVIMEDEUVIMED entdecken
Crossref

Efficacy of ruxolitinib for HAVCR2 mutation‐associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children

Qing Zhang iD, Chun-Ju Zhou, Dan-Hong Li, Lei Cui iD, Wei-Jing Li, Hong-Hao Ma, Yun-Ze Zhao iD, Dong Wang, Zhi-Gang Li iD, Tian-You Wang, Li Wei, Yan-Long Duan iD und 1 weitere

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18817 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Qing Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Hematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Ca…. Hauptthemen laut MEDLINE: Panniculitis, Lymphohistiocytosis, Hemophagocytic. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Beijing Municipal Science and Technology Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Frequent germline mutations of HAVCR2 , recently identified in subcutaneous panniculitis‐like T‐cell lymphoma (SPTCL), are associated with an increased risk of hemophagocytic lymphohistiocytosis (HLH). However, SPTCL‐HLH represents a challenge because of the difficulties in treatment with poor survival. Its malignant nature, specifically harbouring HAVCR2 mutations, has also been questioned. To better understand its pathology and treatment, we analysed the clinical data of six patients diagnosed at our centre. The median age at onset was 10.5 years (range, 0.8–12.4). Five patients presented with skin lesions of subcutaneous nodules/plaques and/or ulceration. All patients developed HLH; notably, one infant only had HLH without skin involvement. Histopathologically, only two patients were diagnosed with SPTCL and three were reported as panniculitis with no sufficient evidence of lymphoma. Genetically, germline homozygous mutation of HAVCR2 (p.Y82C) was identified in all patients, with a median diagnosis time of 4.6 months. All patients initially received corticosteroids, immunosuppressants or chemotherapy, achieving unfavourable responses. Strikingly, they responded well to ruxolitinib targeting inflammatory cytokines, allowing rapid disease resolution and/or long‐term maintenance of remission. The excellent efficacy of ruxolitinib highlights this disease as an inflammatory condition instead of neoplastic nature and indicates novel agents targeting key inflammatory pathways as an encouraging approach for this disease entity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PanniculitisLymphohistiocytosis, HemophagocyticGerm-Line MutationHepatitis A Virus Cellular Receptor 2Child, PreschoolHumansInfantChildNitrilesPyrazolesPyrimidinesLymphoma, T-Cell

Stichwörter der Autor:innen

HAVCR2 mutationhemophagocytic lymphohistiocytosisruxolitinibsubcutaneous T-cell lymphoma

Substanzen

Hepatitis A Virus Cellular Receptor 2HAVCR2 protein, humanruxolitinibNitrilesPyrazolesPyrimidines

Autor:innen und Institutionen

  • Hematologic Disease Laboratory, Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Childre…
  • Department of Pathology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Departments of Hematology, Hongqi Hospital Affiliated to Mudanjiang Medical University, Heilongjiang, China.
  • Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics (Capital Medical University), Key Laboratory of Major Diseases in Children, Ministry of Education, Beijin…
  • Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

ORCID-Profile: Qing Zhang, Lei Cui, Yun-Ze Zhao, Zhi-Gang Li, Yan-Long Duan, Rui Zhang

Förderung

  • Beijing Municipal Science and Technology Commission

Zitieren

APA

Zhang, Q., Zhou, C. J., Li, D. H., Cui, L., Li, W. J., Ma, H. H., Zhao, Y. Z., Wang, D., Li, Z. G., Wang, T. Y., Wei, L., Duan, Y. L., & Zhang, R. (2023). Efficacy of ruxolitinib for HAVCR2 mutation‐associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children. British Journal of Haematology. https://doi.org/10.1111/bjh.18817

Vancouver

Zhang Q, Zhou CJ, Li DH, Cui L, Li WJ, Ma HH, et al. Efficacy of ruxolitinib for HAVCR2 mutation‐associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children. British Journal of Haematology. 2023. doi:10.1111/bjh.18817

BibTeX
@article{Zhang2023,
  author = {Zhang, Qing and Zhou, Chun-Ju and Li, Dan-Hong and Cui, Lei and Li, Wei-Jing and Ma, Hong-Hao and Zhao, Yun-Ze and Wang, Dong and Li, Zhi-Gang and Wang, Tian-You and Wei, Li and Duan, Yan-Long and Zhang, Rui},
  title = {Efficacy of ruxolitinib for HAVCR2 mutation‐associated hemophagocytic lymphohistiocytosis and panniculitis manifestations in children},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18817}
}
Kostenlos starten →